Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jun 1;138(6):601-608.
doi: 10.1001/jamaophthalmol.2020.0531.

Incidence and Survival of Patients With Conjunctival Melanoma in Europe

Gianni Virgili  1 , Mariacristina Parravano  2 , Gemma Gatta  3 , Riccardo Capocaccia  4 , Cinzia Mazzini  1 , Sandra Mallone  5 , Laura Botta  3 ; RARECAREnet Working Group
Affiliations
Multicenter Study

Incidence and Survival of Patients With Conjunctival Melanoma in Europe

Gianni Virgili et al. JAMA Ophthalmol. .

Abstract

Importance: Conjunctival melanoma (CM) is a rare ocular tumor. Estimates of incidence and survival of patients with CM are important to researchers and policy makers.

Objective: To estimate incidence and survival of patients with CM in Europe.

Design, setting, and participants: This population-based cohort study used data from 41 European cancer registries adhering to the RARECAREnet project. All individuals diagnosed as having malignant CM from January 1995 to December 2007 coded according to the International Classification of Diseases for Oncology, Third Edition codes C69.0 (conjunctiva) and 8720-8780 (melanoma) were included. Analysis began March 2019.

Main outcomes and measures: Trend estimates for incidence and for 5-year relative survival (the ratio of the measured survival of patients to the expected survival in the general population for the same country, age, sex, and calendar year). Crude, age-standardized, and bayesian incidence rates were calculated. Five-year relative survival was calculated by the Ederer II method with the cohort and period approach.

Results: A total of 724 patients 15 years or older (512 [70.7%] were 55 years or older; 366 [50.6%] were female) were analyzed with an overall crude incidence of CM (per 1 000 000 person/y) of 0.46 (95% CI, 0.42-0.49). Crude incidence was similar in men and women (0.48; 95% CI, 0.44-0.54 and 0.46; 95% CI, 0.41-0.51, respectively) and increased with age. Age-standardized incidence increased over time only in men and was the highest in Norway and the Netherlands (more than 0.70). Only 1 case in 14 years was estimated to occur in Iceland vs about 20 cases per year in large countries such as France and Germany. Percentage of 5-year survival (83.5 overall; 95% CI, 78.6-87.3) was not different between adult and elderly patients but showed large geographical disparities across European regions (range, 66-89) and improved markedly in male patients (from 76 in 1995-1998 to 86 in 2003-2007, with a difference of 10.2 [95% CI, 1.3-19.2]; P < .05) becoming similar to that of women in the last period.

Conclusions and relevance: Although these data are only available through 2007 and based on registries not uniformly covering the European population, the study provides the first Europe-wide estimates of the incidence and relative survival of patients with CM using population-based data. Geographical differences in survival indicate room for outcome improvement in Southern, Northern, and Eastern European countries.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Parravano reports personal fees from Allergan, Bayer, and Novartis outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Bayesian Incidence Rates and 95% CI With the Number of Cases for Each Registry and Time, Expected to Observe 1 Case in Each Country
aNo country-level coverage was available. The registries providing data are shown in eTable 1 in the Supplement.
Figure 2.
Figure 2.. Temporal Trends of Age-Adjusted Incidence Rate and 5-Year Relative Survival in Europe Across 1995-1998, 1999-2002, and 2003-2007
See this image and copyright information in PMC

Comment in

References

    1. Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42(4):321-350. doi:10.1016/S0039-6257(97)00122-7 - DOI - PubMed
    1. Shields CL, Markowitz JS, Belinsky I, et al. . Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389-95.e1, 2. doi:10.1016/j.ophtha.2010.06.021 - DOI - PubMed
    1. Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol. 2010;21(5):380-386. doi:10.1097/ICU.0b013e32833b7aab - DOI - PubMed
    1. Kao A, Afshar A, Bloomer M, Damato B. Management of primary acquired melanosis, nevus, and conjunctival melanoma. Cancer Control. 2016;23(2):117-125. doi:10.1177/107327481602300205 - DOI - PubMed
    1. Vora GK, Demirci H, Marr B, Mruthyunjaya P. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2017;62(1):26-42. doi:10.1016/j.survophthal.2016.06.001 - DOI - PMC - PubMed

Publication types